SCHEMBL11032471

SCHEMBL11032471

Cc1ccccc1NC(=O)n1cc[c]n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
HPGD P15428 4/20 0.47
ALDH1A1 P00352 1/20 0.47
ITGB1 P05556 3/20 0.47
ITGA4 P13612 3/20 0.47
BCHE P06276 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ITGB3 P05106 2/20 0.43
ITGAV P06756 2/20 0.43
ITGA5 P08648 2/20 0.43
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL760516 0.82 RAB9A (0.49) NPC1RAB9AALDH1A1KMT2APOLB
SCHEMBL11028201 0.79 MEN1 (0.52) RAB9AALDH1A1LMNAMAPTKMT2A
SCHEMBL752278 0.77 MEN1 (0.49) NPC1RAB9AHPGDALDH1A1LMNA
SCHEMBL11029424 0.76 RAB9A (0.46) NPC1RAB9AALDH1A1BCHEKMT2A
SCHEMBL28325088 0.75 NPC1 (0.50) NPC1RAB9AHPGDALDH1A1ITGB1
SCHEMBL11027629 0.74 ALDH1A1 (0.52) NPC1RAB9AHPGDALDH1A1KMT2A
SCHEMBL755622 0.72 NPC1 (0.44) NPC1RAB9AALDH1A1LMNAMAPT
SCHEMBL752990 0.72 MAPT (0.54) MAPTMAPK1KMT2APOLB
SCHEMBL28325062 0.70 ITGB1 (0.56) NPC1RAB9AHPGDALDH1A1ITGB1
SCHEMBL11032892 0.70 MAPT (0.54) NPC1RAB9ABCHEMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD NPC1 732/4885RAB9A 677/4885HPGD 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.